Apricitabine

Medical Advocates
Apricitabine (AVX754 SPD754)

Conference Reports, Abstracts
and Posters

XVII International AIDS Conference
4th IAS Conference
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference

Apricitabine Main Page

New and Noteworthy

Home Page

Last Update: December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

XVII International AIDS Conference

POWERPOINT POSTER PRESENTATION
Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients
S Cox
Poster Presentation

4th IAS Conference on HIV Pathogenesis, Treatment,
and Prevention

Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected
patients failing therapy with M184V and NRTI resistance
Cahn P, Altclas J, Martins M
Abstract

Eighth International Congress on Drug Therapy
in HIV Infection

Disease state model for apricitabine in treatment naīve HIV-infected patients
Smith P , Forrest A. , Sawyer J.
Abstract

XVI International AIDS Conference

In vitro pharmacology of Apricitabine, a new NRTI for HIV
J Sawyer, S Cox
Abstract
Pharmacokinetics of apricitabine in healthy volunteers and HIV-infected individuals
J Sawyer, C Struthers Semple
Abstract

Apricitabine Main Page

New and Noteworthy

Home Page

Apricitabine Conference Citations